LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND1 V: g, E, {( P
THERAPE UTIC PERSPECTIVES) b+ ^3 J2 c9 i! }2 f. m9 T
J. Mazieres, S. Peters3 R+ l2 P( d: V0 [& R
Introduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic8 t3 Z( C) V( u+ m p5 J/ P4 U
outcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted
/ D7 w6 m* }: [0 \treatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2
. ?7 k$ A6 K' D& W6 ?treatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations
& z- W' j W/ k& uand 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;
& p# ?2 L% q2 H: K! ndisease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for" I& w- n1 ^: |5 W2 L
trastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to. @' a$ F4 r2 h: X/ ]
lapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and
0 K, Y1 N( O7 K! ^: g22.9 months for respectively early stage and stag e IV patients." C$ O3 x3 H! b- H7 s
Conclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,
: g1 h8 V- \. F1 d+ F1 w+ Breinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .
$ R q7 W9 k S/ a N b/ jHER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative! [, ~, n, r# |8 c0 @6 c8 h C
clinicaltrials.& q/ l$ |. D3 H' K
|
显身卡
